ORYX GmbH & Co. KG news

ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today reported new results on the mode of action of oncolytic virus ParvOryx in human ovarian cancer explants. ParvOryx, a wild type rat oncolytic parvovirus (H-1PV), had successfully completed two Phase I/IIa clinical trials in glioblastoma and pancreatic cancer, respectively. The new data show that ParvOryx may also be effective in targeting ovarian cancer and further confirm the mode of action of t

ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today provided an update on the development strategy for oncolytic virus ParvOryx, a wild type rat oncolytic parvovirus (H-1PV). So far, two Phase I/IIa clinical trials in recurrent glioblastoma (rGBM) and metastatic, inoperable pancreatic cancer have been completed successfully. Moreover, in a follow-up program in patients with recurrent glioblastoma, metastatic colorectal cancer and NSCLC, the enhan

ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today published positive clinical trial results from a dose-escalating Phase I/IIa trial with oncolytic virus ParvOryx in metastatic, inoperable pancreatic cancer.

ParvOryx, a wild type rat oncolytic parvovirus (H-1PV), was evaluated in an open label study in seven patients with metastatic, inoperable pancreatic cancer. The patients received ParvOryx at three increasing dose levels, partly adm